JP2017527582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527582A5 JP2017527582A5 JP2017513488A JP2017513488A JP2017527582A5 JP 2017527582 A5 JP2017527582 A5 JP 2017527582A5 JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017527582 A5 JP2017527582 A5 JP 2017527582A5
- Authority
- JP
- Japan
- Prior art keywords
- lif
- pharmaceutical composition
- agent
- composition according
- antagonizes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048770P | 2014-09-10 | 2014-09-10 | |
| US62/048,770 | 2014-09-10 | ||
| PCT/US2015/049461 WO2016040657A1 (en) | 2014-09-10 | 2015-09-10 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527582A JP2017527582A (ja) | 2017-09-21 |
| JP2017527582A5 true JP2017527582A5 (enExample) | 2018-10-18 |
Family
ID=55459579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513488A Pending JP2017527582A (ja) | 2014-09-10 | 2015-09-10 | Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170247446A1 (enExample) |
| EP (1) | EP3191129A4 (enExample) |
| JP (1) | JP2017527582A (enExample) |
| CN (1) | CN106687134A (enExample) |
| AU (1) | AU2015314980A1 (enExample) |
| CA (1) | CA2958685A1 (enExample) |
| WO (1) | WO2016040657A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173483A1 (en) * | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| EP3407820A4 (en) | 2016-01-26 | 2019-11-06 | Cyberdontics, Inc. | Automated dental treatment system |
| SI3555132T1 (sl) | 2016-12-19 | 2024-04-30 | Medimmune Limited | Protitelesa proti LIF in njihove uporabe |
| US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| WO2019197903A1 (en) * | 2018-04-12 | 2019-10-17 | Mosaic Biomedicals Slu | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer |
| MX2020011894A (es) | 2018-05-10 | 2021-03-29 | Cyberdontics Usa Inc | Taladro dental automatizado. |
| SG11202011170YA (en) * | 2018-05-14 | 2020-12-30 | Medimmune Ltd | Antibodies against lif and dosage forms thereof |
| EP3806899A2 (en) * | 2018-06-18 | 2021-04-21 | MedImmune Limited | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| EP3959199A4 (en) * | 2019-04-24 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treating ras-mutant cancers |
| EP4208122B1 (en) | 2020-09-03 | 2026-02-11 | Perceptive Technologies, Inc. | System for directing an automated dental drill |
| WO2024229470A1 (en) | 2023-05-04 | 2024-11-07 | Perceptive Technologies, Inc. | Robotic dental system and method of preparing for a robotic dental procedure |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| SG2014008304A (en) * | 2012-02-01 | 2014-06-27 | Compugen Ltd | C10rf32 antibodies, and uses thereof for treatment of cancer |
| WO2015040243A2 (en) * | 2013-09-23 | 2015-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis |
-
2015
- 2015-09-10 JP JP2017513488A patent/JP2017527582A/ja active Pending
- 2015-09-10 EP EP15840805.4A patent/EP3191129A4/en not_active Withdrawn
- 2015-09-10 AU AU2015314980A patent/AU2015314980A1/en not_active Abandoned
- 2015-09-10 CN CN201580048473.1A patent/CN106687134A/zh active Pending
- 2015-09-10 WO PCT/US2015/049461 patent/WO2016040657A1/en not_active Ceased
- 2015-09-10 US US15/508,036 patent/US20170247446A1/en not_active Abandoned
- 2015-09-10 CA CA2958685A patent/CA2958685A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mei et al. | Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand | |
| JP2021521194A5 (enExample) | ||
| JP2021526132A5 (enExample) | ||
| JP2007526455A5 (enExample) | ||
| JP2017517520A5 (enExample) | ||
| CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| JP2016041733A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2016536361A5 (enExample) | ||
| JP2013173775A5 (enExample) | ||
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2013520442A5 (enExample) | ||
| JP2013523843A5 (enExample) | ||
| JP2022511394A5 (enExample) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2017533222A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| JP2019533651A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| JP2013541586A5 (enExample) | ||
| JP2017516827A5 (enExample) |